SUMMIT

Clinical Question

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity (BMI ≥30 kg/m²), does treatment with once-weekly Tirzepatide (up to 15mg once weekly) reduce death from cardiovascular causes or worsening heart failure and improve symptoms, physical limitations and exercise function compared to placebo?

Bottom Line

In patients with HFpEF and obesity, Tirzepatide (up to 15mg once weekly) significantly improved heart failure–related symptoms and physical limitations, increased exercise capacity, and led to decreased worsening of heart failure or cardiovascular death over 52 weeks compared to placebo.

Outcomes

Comparisons are intensive therapy vs. standard therapy.